PMID-sentid Pub_year Sent_text comp_official_name comp_offset protein_name organism prot_offset 2189207-5 1990 In the United States, the NRS/CHOL was organized as part of the National Reference System for the Clinical Laboratory. chol 30-34 sphingolipid transporter 1 (putative) Homo sapiens 26-29 2189207-6 1990 The major organizational components of the NRS/CHOL include the National Institute for Standards and Technology, the CDC, the CRMN, the CAP, the AAB, regional reference programs, and manufacturers of cholesterol diagnostic products. Cholesterol 200-211 sphingolipid transporter 1 (putative) Homo sapiens 43-46 2189207-9 1990 The NRS/CHOL has contributed much to the success of clinical epidemiologic and research and development investigations in coronary heart disease. chol 8-12 sphingolipid transporter 1 (putative) Homo sapiens 4-7 34199980-6 2021 The former configuration has more intense Normal Raman Scattering, NRS, on TiO2 surfaces and was studied with Time-Dependent Density Functional Theory, TD-DFT, frequency-dependent Raman simulations. titanium dioxide 75-79 sphingolipid transporter 1 (putative) Homo sapiens 67-70 34500008-0 2021 Perfluorooctane sulfonate induces autophagy-dependent lysosomal membrane permeabilization by weakened interaction between tyrosinated alpha-tubulin and spinster 1. perfluorooctane sulfonic acid 0-25 sphingolipid transporter 1 (putative) Homo sapiens 152-162 34500008-2 2021 In previous study, we found that PFOS induced autophagy-dependent lysosomal membrane permeabilization (LMP) in hepatocytes, and siRNA against lysosomal permease spinster 1 (SPNS1) relieved PFOS-induced LMP. perfluorooctane sulfonic acid 189-193 sphingolipid transporter 1 (putative) Homo sapiens 161-171 34500008-2 2021 In previous study, we found that PFOS induced autophagy-dependent lysosomal membrane permeabilization (LMP) in hepatocytes, and siRNA against lysosomal permease spinster 1 (SPNS1) relieved PFOS-induced LMP. perfluorooctane sulfonic acid 189-193 sphingolipid transporter 1 (putative) Homo sapiens 173-178 34500008-7 2021 SPNS1-tyrosinated alpha-tubulin interaction was disrupted subsequently, which led to LMP eventually. (2~{s},3~{r},4~{s})-2-[(2~{s},3~{r})-1,3-Bis(Oxidanyl)-1-Oxidanylidene-Butan-2-Yl]-4-[(3~{s},5~{s})-5-(Dimethylcarbamoyl)pyrrolidin-3-Yl]sulfanyl-3-Methyl-3,4-Dihydro-2~{h}-Pyrrole-5-Carboxylic Acid 85-88 sphingolipid transporter 1 (putative) Homo sapiens 0-5 34500008-8 2021 We also found that stable high-expression of SPNS1 in hepatocytes accelerated lysosomal acidification, and deteriorated PFOS-induced LMP. perfluorooctane sulfonic acid 120-124 sphingolipid transporter 1 (putative) Homo sapiens 45-50 34500008-9 2021 This study pointed out that SPNS1-tyrosinated alpha-tubulin interaction mediated the cross-talk between autophagy and LMP induced by PFOS, shedding new light on the mechanism of PFOS hepatotoxicity. (2~{s},3~{r},4~{s})-2-[(2~{s},3~{r})-1,3-Bis(Oxidanyl)-1-Oxidanylidene-Butan-2-Yl]-4-[(3~{s},5~{s})-5-(Dimethylcarbamoyl)pyrrolidin-3-Yl]sulfanyl-3-Methyl-3,4-Dihydro-2~{h}-Pyrrole-5-Carboxylic Acid 118-121 sphingolipid transporter 1 (putative) Homo sapiens 28-33 34500008-9 2021 This study pointed out that SPNS1-tyrosinated alpha-tubulin interaction mediated the cross-talk between autophagy and LMP induced by PFOS, shedding new light on the mechanism of PFOS hepatotoxicity. perfluorooctane sulfonic acid 133-137 sphingolipid transporter 1 (putative) Homo sapiens 28-33 34842731-4 2021 Sphingolipid transporter 1 (spns1), a highly conserved gene encoding a putative late endosome/lysosome carbohydrate/H+ symporter, plays a pivotal role in maintaining optimal lysosomal pH and spns1-/- mutants undergo premature senescence. Carbohydrates 103-115 sphingolipid transporter 1 (putative) Homo sapiens 0-26 34842731-4 2021 Sphingolipid transporter 1 (spns1), a highly conserved gene encoding a putative late endosome/lysosome carbohydrate/H+ symporter, plays a pivotal role in maintaining optimal lysosomal pH and spns1-/- mutants undergo premature senescence. Carbohydrates 103-115 sphingolipid transporter 1 (putative) Homo sapiens 28-33 34356423-0 2021 Assessment and Prediction of Water Resources Vulnerability Based on a NRS-RF Model: A Case Study of the Song-Liao River Basin, China. Water 29-34 sphingolipid transporter 1 (putative) Homo sapiens 70-73 34356423-3 2021 Based on the constructed indicator system of water resources vulnerability assessment in Song-Liao River Basin, this paper uses the neighborhood rough set (abbreviated as NRS) method to reduce the dimensionality of the original indicator system to remove redundant attributes. Water 45-50 sphingolipid transporter 1 (putative) Homo sapiens 171-174 34968019-6 2021 The most pronounced clinical effect (PCFS) was obtained after 1 mth of therapy with vinpocetine and 20 days with aceclofenac (NRS-P). aceclofenac 113-124 sphingolipid transporter 1 (putative) Homo sapiens 126-129 35538896-4 2022 Despite the improvement of bacterial load, WBS, Qol and NRS was evident in all 3 groups, the analysis of our results demonstrates that the application of zinc oxide bandage, directly in contact with the wound bed and/or the perilesional skin, resulted in a higher improvement and a significant reduction of WBS and bacterial load. Zinc Oxide 154-164 sphingolipid transporter 1 (putative) Homo sapiens 56-59 35167059-11 2022 Dexmedetomidine significantly reduced NRS scores comparing to placebo at 3 months (p = 0.018), while at 6 months, lidocaine was found superior to placebo (p = 0.02), but not to dexmedetomidine, in preventing neuropathic pain (DN4 < 4). Dexmedetomidine 0-15 sphingolipid transporter 1 (putative) Homo sapiens 38-41 34966018-7 2022 Results: Compared with the preoperative NRS scores, the postoperative NRS scores decreased significantly; the NRS scores of the DCRF group was lower than that of the CRF group at all time points from 6 months to 2 years following the operation. dcrf 128-132 sphingolipid transporter 1 (putative) Homo sapiens 110-113 35190644-5 2022 A meta-analysis including nine studies demonstrated a weak negative correlation between ANI and NRS for pain assessment in individuals in the post-anesthetic recovery room (r = - 0.0984, 95% CI = - 0.397 to 0.220, I2 = 95.82%), or in those submitted to electrical stimulus (r = - 0.089; 95% CI = - 0.390 to 0.228, I2 = 0%). 1-Naphthylisothiocyanate 88-91 sphingolipid transporter 1 (putative) Homo sapiens 96-99 6543460-3 1984 The intracellular ATP was released by TCA or NRS -reagent, and the ATP levels were measured directly from an aliquot of the growth medium without any extraction or precipitation steps. Adenosine Triphosphate 18-21 sphingolipid transporter 1 (putative) Homo sapiens 45-48 2647375-5 1989 Both the manufacturers and laboratorians need to standardize the measurement for cholesterol so that the accuracy base is traceable to the NCCLS NRS/CHOL. Cholesterol 81-92 sphingolipid transporter 1 (putative) Homo sapiens 145-148 2647379-1 1989 The NRS/CHOL is a reality that is progressively becoming the way in which accuracy of cholesterol results is being ensured. chol 8-12 sphingolipid transporter 1 (putative) Homo sapiens 4-7 2647379-1 1989 The NRS/CHOL is a reality that is progressively becoming the way in which accuracy of cholesterol results is being ensured. Cholesterol 86-97 sphingolipid transporter 1 (putative) Homo sapiens 4-7 2647379-2 1989 Proof of traceability to NRS/CHOL within each segment of the clinical laboratory, now an expectation, will soon be the norm that makes a sound conceptual reference system into an everyday reality that reaches into the many thousands of working sites that measure cholesterol in serum on patient samples. Cholesterol 263-274 sphingolipid transporter 1 (putative) Homo sapiens 25-28 18963969-0 1985 Extraction chromatography of palladium and platinum complexes with nitroso-R-salt. Palladium 29-38 sphingolipid transporter 1 (putative) Homo sapiens 67-81 18963969-0 1985 Extraction chromatography of palladium and platinum complexes with nitroso-R-salt. Platinum 43-51 sphingolipid transporter 1 (putative) Homo sapiens 67-81 18963969-1 1985 The retention of palladium and platinum complexes with nitroso-R-salt on silica gel treated with Aliquat 336 has been investigated. Platinum 31-39 sphingolipid transporter 1 (putative) Homo sapiens 55-69 18963969-1 1985 The retention of palladium and platinum complexes with nitroso-R-salt on silica gel treated with Aliquat 336 has been investigated. Silica Gel 73-83 sphingolipid transporter 1 (putative) Homo sapiens 55-69 18963969-1 1985 The retention of palladium and platinum complexes with nitroso-R-salt on silica gel treated with Aliquat 336 has been investigated. aliquat 97-104 sphingolipid transporter 1 (putative) Homo sapiens 55-69 18963969-2 1985 The complexation of platinum with nitroso-R-salt (NRS) requires heating of H(2)PtCl(6) with an excess of NRS at 100 degrees . Platinum 20-28 sphingolipid transporter 1 (putative) Homo sapiens 34-48 18963969-2 1985 The complexation of platinum with nitroso-R-salt (NRS) requires heating of H(2)PtCl(6) with an excess of NRS at 100 degrees . Platinum 20-28 sphingolipid transporter 1 (putative) Homo sapiens 50-53 18963969-2 1985 The complexation of platinum with nitroso-R-salt (NRS) requires heating of H(2)PtCl(6) with an excess of NRS at 100 degrees . Platinum 20-28 sphingolipid transporter 1 (putative) Homo sapiens 105-108 18963969-2 1985 The complexation of platinum with nitroso-R-salt (NRS) requires heating of H(2)PtCl(6) with an excess of NRS at 100 degrees . h(2)ptcl(6) 75-86 sphingolipid transporter 1 (putative) Homo sapiens 34-48 18963969-2 1985 The complexation of platinum with nitroso-R-salt (NRS) requires heating of H(2)PtCl(6) with an excess of NRS at 100 degrees . h(2)ptcl(6) 75-86 sphingolipid transporter 1 (putative) Homo sapiens 50-53 4023277-2 1985 The Co-NRS complex is extracted substoichiometrically into Capriquat-CHCl3 at pH 6.5-9.0 in 20 min of shaking time. capriquat-chcl3 59-74 sphingolipid transporter 1 (putative) Homo sapiens 7-10 33566629-11 2021 NACD+PRP was found to be noninferior to NACD+corticosteroids with regard to the mean decrease of NRS scores (4.34 vs 3.56; P = .003). nacd 0-4 sphingolipid transporter 1 (putative) Homo sapiens 97-100 18960936-0 1971 Extraction with long-chain amines-V Colorimetric determination of cobalt with nitroso-R salt. Amines 27-33 sphingolipid transporter 1 (putative) Homo sapiens 78-92 18960936-0 1971 Extraction with long-chain amines-V Colorimetric determination of cobalt with nitroso-R salt. Cobalt 66-72 sphingolipid transporter 1 (putative) Homo sapiens 78-92 18960936-1 1971 The colorimetric determination of cobalt with nitroso-R salt (NRS) has been modified and improved by the introduction of extraction of the Co-NRS chelate into a chloroform solution of trioctylmethylammonium chloride. Cobalt 34-40 sphingolipid transporter 1 (putative) Homo sapiens 46-60 18960936-1 1971 The colorimetric determination of cobalt with nitroso-R salt (NRS) has been modified and improved by the introduction of extraction of the Co-NRS chelate into a chloroform solution of trioctylmethylammonium chloride. Cobalt 34-40 sphingolipid transporter 1 (putative) Homo sapiens 62-65 18960936-1 1971 The colorimetric determination of cobalt with nitroso-R salt (NRS) has been modified and improved by the introduction of extraction of the Co-NRS chelate into a chloroform solution of trioctylmethylammonium chloride. Cobalt 34-40 sphingolipid transporter 1 (putative) Homo sapiens 142-145 18960936-1 1971 The colorimetric determination of cobalt with nitroso-R salt (NRS) has been modified and improved by the introduction of extraction of the Co-NRS chelate into a chloroform solution of trioctylmethylammonium chloride. Chloroform 161-171 sphingolipid transporter 1 (putative) Homo sapiens 46-60 18960936-1 1971 The colorimetric determination of cobalt with nitroso-R salt (NRS) has been modified and improved by the introduction of extraction of the Co-NRS chelate into a chloroform solution of trioctylmethylammonium chloride. Chloroform 161-171 sphingolipid transporter 1 (putative) Homo sapiens 62-65 18960936-1 1971 The colorimetric determination of cobalt with nitroso-R salt (NRS) has been modified and improved by the introduction of extraction of the Co-NRS chelate into a chloroform solution of trioctylmethylammonium chloride. Chloroform 161-171 sphingolipid transporter 1 (putative) Homo sapiens 142-145 18960936-1 1971 The colorimetric determination of cobalt with nitroso-R salt (NRS) has been modified and improved by the introduction of extraction of the Co-NRS chelate into a chloroform solution of trioctylmethylammonium chloride. trioctylmethylammonium 184-215 sphingolipid transporter 1 (putative) Homo sapiens 46-60 18960936-1 1971 The colorimetric determination of cobalt with nitroso-R salt (NRS) has been modified and improved by the introduction of extraction of the Co-NRS chelate into a chloroform solution of trioctylmethylammonium chloride. trioctylmethylammonium 184-215 sphingolipid transporter 1 (putative) Homo sapiens 62-65 18960936-1 1971 The colorimetric determination of cobalt with nitroso-R salt (NRS) has been modified and improved by the introduction of extraction of the Co-NRS chelate into a chloroform solution of trioctylmethylammonium chloride. trioctylmethylammonium 184-215 sphingolipid transporter 1 (putative) Homo sapiens 142-145 33197270-4 2021 Differential (ibuprofen or capsaicin) response was defined when change-from-baseline pain intensity scores (0-10 NRS) differed by >=1 between treatments in >=2 cycles within a participant. Ibuprofen 14-23 sphingolipid transporter 1 (putative) Homo sapiens 113-116 33197270-4 2021 Differential (ibuprofen or capsaicin) response was defined when change-from-baseline pain intensity scores (0-10 NRS) differed by >=1 between treatments in >=2 cycles within a participant. Capsaicin 27-36 sphingolipid transporter 1 (putative) Homo sapiens 113-116 32940751-6 2021 RESULTS: Following administration of methylprednisolone were significantly lower levels of CRP on all the four post-operative days; leukocytosis on the second day; the VAS/NRS score at rest after six, 12, and 18 hours post-operatively, diminished the dose of parenteral opioid preparations (oxycodone hydrochloride), the duration of analgesia by peripheral nerve block was significantly higher as compared with the placebo group (p < 0.000001). Methylprednisolone 37-55 sphingolipid transporter 1 (putative) Homo sapiens 172-175 33583225-3 2021 Results: The NRS scores were correlated with the VITA Red but not with VITA Blue. vita red 49-57 sphingolipid transporter 1 (putative) Homo sapiens 13-16 33181580-9 2021 Median score for total pain changed from NRS 6.4 to 6.1 from baseline to week 5 on terbutaline with an average effect during the treatment period as compared to placebo of 0.13 (95% CI -0.12;0.38, p = 0.32). Terbutaline 83-94 sphingolipid transporter 1 (putative) Homo sapiens 41-44 33181580-10 2021 Median score for total pain on imipramine changed from NRS 6.6 to 4.8 with an average effect as compared to placebo of -1.17 (95% CI -1.42; -0.92, p < 0.001). Imipramine 31-41 sphingolipid transporter 1 (putative) Homo sapiens 55-58 33566629-13 2021 However, clinically relevant differences in favor of NACD+PRP were only seen at the 6-month follow-up for NRS and CMS scores, whereas at the 6-week follow-up a clinically relevant difference in favor of NACD+corticosteroids was found for all clinical scores except for the NRS. nacd 53-57 sphingolipid transporter 1 (putative) Homo sapiens 106-109 33594813-8 2021 The results showed that patients of both combination therapy group (pregabalin+morphine) and monotherapy group (morphine) achieved similar analgesic efficacy, demonstrated by NRS (2.4 +- 0.9 vs. 2.6 +- 0.9; combination vs. monotherapy) at the end of the study. Pregabalin 68-78 sphingolipid transporter 1 (putative) Homo sapiens 175-178 33594813-8 2021 The results showed that patients of both combination therapy group (pregabalin+morphine) and monotherapy group (morphine) achieved similar analgesic efficacy, demonstrated by NRS (2.4 +- 0.9 vs. 2.6 +- 0.9; combination vs. monotherapy) at the end of the study. Morphine 79-87 sphingolipid transporter 1 (putative) Homo sapiens 175-178 33594813-8 2021 The results showed that patients of both combination therapy group (pregabalin+morphine) and monotherapy group (morphine) achieved similar analgesic efficacy, demonstrated by NRS (2.4 +- 0.9 vs. 2.6 +- 0.9; combination vs. monotherapy) at the end of the study. Morphine 112-120 sphingolipid transporter 1 (putative) Homo sapiens 175-178 33066973-6 2021 MAIN OUTCOME MEASURE(S): NRS-DYS and NRS-NMPP. nmpp 41-45 sphingolipid transporter 1 (putative) Homo sapiens 37-40 33066973-9 2021 Standard errors of measurement were 2.99 (EM-I) and 2.86 (EM-II) for NRS-DYS and 1.74 (EM-I) and 1.71 (EM-II) for NRS-NMPP. nmpp 118-122 sphingolipid transporter 1 (putative) Homo sapiens 114-117 33066973-11 2021 Based on these results, clinically meaningful changes were defined as a reduction of 4 points for NRS-DYS and 2 points for NRS-NMPP. nmpp 127-131 sphingolipid transporter 1 (putative) Homo sapiens 123-126 32617631-5 2020 After surgery patients received piritramide to achieve a pain score of <=3 on the numeric rating scale (NRS 0-10). Pirinitramide 32-43 sphingolipid transporter 1 (putative) Homo sapiens 104-107 33506805-11 2020 Other methods reduced pain and disability at W1, but further reduction of mean NRS values during the follow-up period was only evident in the CM group (32.25%), very mild in the MM (19.35%) and LT groups (18.75%), and the TT group actually demonstrated a regression (-5.58%). 6-thiotheophylline 222-224 sphingolipid transporter 1 (putative) Homo sapiens 79-82 32564499-5 2020 RESULTS: Perceived pain (NRS) was significantly reduced in BB intervention (5.6+-2.3 to 3.4+-2.6, p<0.001), compared to SS (5.2+-2.1 to 4.8+-2.3, p=0.78), during the first 30-minute phase, as well as at the week"s end (to 3.9+-2.5 compared to 5.5+-2.6 respectively, p<0.001). boeravinone B 59-61 sphingolipid transporter 1 (putative) Homo sapiens 25-28 32325440-1 2020 Co(OH)2 nanosheets/Cu(OH)2 nanorods (Co(OH)2 Nss/Cu(OH)2 Nrs) composite electrode for non-enzymatic glucose sensing was fabricated by electrodepositing Co(OH)2 Nss on Cu(OH)2 nanorods substrate grown directly on the copper sheet via a simple one-step reaction. co(oh) 0-6 sphingolipid transporter 1 (putative) Homo sapiens 57-60 32325440-1 2020 Co(OH)2 nanosheets/Cu(OH)2 nanorods (Co(OH)2 Nss/Cu(OH)2 Nrs) composite electrode for non-enzymatic glucose sensing was fabricated by electrodepositing Co(OH)2 Nss on Cu(OH)2 nanorods substrate grown directly on the copper sheet via a simple one-step reaction. cu(oh) 19-25 sphingolipid transporter 1 (putative) Homo sapiens 57-60 32325440-1 2020 Co(OH)2 nanosheets/Cu(OH)2 nanorods (Co(OH)2 Nss/Cu(OH)2 Nrs) composite electrode for non-enzymatic glucose sensing was fabricated by electrodepositing Co(OH)2 Nss on Cu(OH)2 nanorods substrate grown directly on the copper sheet via a simple one-step reaction. cu(oh) 49-55 sphingolipid transporter 1 (putative) Homo sapiens 57-60 32325440-1 2020 Co(OH)2 nanosheets/Cu(OH)2 nanorods (Co(OH)2 Nss/Cu(OH)2 Nrs) composite electrode for non-enzymatic glucose sensing was fabricated by electrodepositing Co(OH)2 Nss on Cu(OH)2 nanorods substrate grown directly on the copper sheet via a simple one-step reaction. Glucose 100-107 sphingolipid transporter 1 (putative) Homo sapiens 57-60 32325440-1 2020 Co(OH)2 nanosheets/Cu(OH)2 nanorods (Co(OH)2 Nss/Cu(OH)2 Nrs) composite electrode for non-enzymatic glucose sensing was fabricated by electrodepositing Co(OH)2 Nss on Cu(OH)2 nanorods substrate grown directly on the copper sheet via a simple one-step reaction. cu(oh) 49-55 sphingolipid transporter 1 (putative) Homo sapiens 57-60 32325440-2 2020 The Co(OH)2 Nss/Cu(OH)2 Nrs composite electrode was characterized by scanning electron microscopy, energy dispersive X-ray spectroscopy, X-ray diffraction, X-ray photoelectron spectroscopy. co(oh) 4-10 sphingolipid transporter 1 (putative) Homo sapiens 24-27 32325440-2 2020 The Co(OH)2 Nss/Cu(OH)2 Nrs composite electrode was characterized by scanning electron microscopy, energy dispersive X-ray spectroscopy, X-ray diffraction, X-ray photoelectron spectroscopy. Copper 16-18 sphingolipid transporter 1 (putative) Homo sapiens 24-27 31075088-12 2019 For mechanical stimuli, NRS was increased following capsaicin (LMM, p < 0.001). Capsaicin 52-61 sphingolipid transporter 1 (putative) Homo sapiens 24-27 30701927-4 2018 Further, there was a sufficient effect (NRS - 2 points), from anesthesia only with ropivacaine, using a system for anesthetizing surgical wounds. Ropivacaine 83-94 sphingolipid transporter 1 (putative) Homo sapiens 40-43 30536525-9 2019 A decrease in NRS scores 1 day after ITB administration was observed in significantly more patients in group A than in group B (P < 0.001). ITB 301 37-40 sphingolipid transporter 1 (putative) Homo sapiens 14-17 29727048-9 2018 A significant reduction of pain was registered on day +7 in the PBM versus sham group (NRS 1 [0-3] vs. 2.5 [1-5], P < 0.006). pbm 64-67 sphingolipid transporter 1 (putative) Homo sapiens 87-90 29590725-6 2017 The DETERMINE checklist elements (illness; reduced intake of fruits, vegetables or dairy products; alcohol consumption; oral health problems; and weight loss) were linked to a higher NRS score. Alcohols 99-106 sphingolipid transporter 1 (putative) Homo sapiens 183-186 29108405-8 2018 The mean NRS pain intensity at 12 hours was 2+-0.9 in the placebo group and 1.5+-0.9 with gabapentin (mean difference: -0.5, 95% CI: 0.15 to 0.81, P=0.003). Gabapentin 90-100 sphingolipid transporter 1 (putative) Homo sapiens 9-12 29104684-3 2017 AIM: This study aimed to investigate the flunarizine effect on serum levels of glutamate and its correlation with headache intensity based on the Numeric Rating Scale for pain (NRS) scores in CTTH patients. Flunarizine 41-52 sphingolipid transporter 1 (putative) Homo sapiens 177-180 29162837-8 2017 We propose that SPNS1-dependent L-leucine export across the lysosomal membrane is a key step for triggering autophagy, and that this mechanism is impaired in NPC-1. Leucine 32-41 sphingolipid transporter 1 (putative) Homo sapiens 16-21 29104684-3 2017 AIM: This study aimed to investigate the flunarizine effect on serum levels of glutamate and its correlation with headache intensity based on the Numeric Rating Scale for pain (NRS) scores in CTTH patients. Glutamic Acid 79-88 sphingolipid transporter 1 (putative) Homo sapiens 177-180 28850378-6 2017 The aims of this study were to ascertain if peripheral intravenous (PIV) cannulation pain would be significantly decreased by using a vapocoolant (V) versus sterile water placebo (S) spray, as determined by a reduction of at least >=1.8 points on numerical rating scale (NRS) after vapocoolant versus placebo spray, the side effects and incidence of side effects from a vapocoolant spray; and whether there were any long term visible skin abnormalities associated with the use of a vapocoolant spray. vapocoolant 134-145 sphingolipid transporter 1 (putative) Homo sapiens 274-277 28699105-15 2017 The important reduction of neuropathic pain, the improvement in NRS and QoL scores after therapy with TP makes it a candidate in the management of patients suffering from neuropathic pain of CIPN also as a first line of therapy. Tapentadol 102-104 sphingolipid transporter 1 (putative) Homo sapiens 64-67 28328759-10 2017 Median (IQR) of NRS at rest (NRSr) (AUC) was 24.5 (19) for the ropivacaine group and 24 (22) for the control group during the first postoperative week (P = .96, 0.0 estimated difference; 95% CI for the difference, -5.0 to 5.0); no difference was found. Ropivacaine 63-74 sphingolipid transporter 1 (putative) Homo sapiens 16-19 28489926-6 2017 Using Receiver Operating Characteristics (ROC) analysis, NRS cut-off points were determined such that they best discriminate between patients having one versus the other outcome for PO, NO and PONO. Polonium 182-184 sphingolipid transporter 1 (putative) Homo sapiens 57-60 27500463-8 2017 Treatment with Sativex resulted in a reduction of NRS for spasticity (P=.01). nabiximols 15-22 sphingolipid transporter 1 (putative) Homo sapiens 51-54 27749351-10 2016 The following is the mean difference in NRS on POD 2 at 9:00 AM among groups: cFNB-LIA (1.2, 95% CI, -0.1 to 2.5; P = .073); sFNB-LIA (1.2, 95% CI, -0.2 to 2.5; P = .097); cFNB-sFNB (0.0, 95% CI, -1.3 to 1.4; P = .996). cfnb-sfnb 172-181 sphingolipid transporter 1 (putative) Homo sapiens 40-43 27261077-12 2016 Postoperative analgesics doses were significantly lower in the NRS-3D group [P = 0.007 (paracetamol); P = 0.123 (metamizole); P = 0.013 (piritramide)]. Acetaminophen 88-99 sphingolipid transporter 1 (putative) Homo sapiens 63-66 27261077-12 2016 Postoperative analgesics doses were significantly lower in the NRS-3D group [P = 0.007 (paracetamol); P = 0.123 (metamizole); P = 0.013 (piritramide)]. Pirinitramide 137-148 sphingolipid transporter 1 (putative) Homo sapiens 63-66 28446396-3 2016 None of the patients used postoperative analgesia pump, and tramadol hydrochoride injection (100 mg) was given in cases with NRS scores > 4 after the surgery. tramadol hydrochoride 60-81 sphingolipid transporter 1 (putative) Homo sapiens 125-128 27749351-9 2016 NRS was 4.6 (95% confidence interval [CI], 3.3-6.0) for the cFNB group, 4.6 (95% CI, 3.3-6.0) for the sFNB group, and 3.4 (95% CI, 2.2-4.8) for the LIA group. cfnb 60-64 sphingolipid transporter 1 (putative) Homo sapiens 0-3 25842937-7 2014 RESULTS: Application of paracetamol + trimeperidin accompanied with effectively reducing of postoperative pain (less than 5 points on the NRS). Acetaminophen 24-35 sphingolipid transporter 1 (putative) Homo sapiens 138-141 26589711-10 2015 The pain reduction achieved individually following ambroxol cream was 2-8 points (NRS) within 5-30 min and lasted for 3-8 h. Pain attacks were reduced in all five patients presenting with this problem. Ambroxol 51-59 sphingolipid transporter 1 (putative) Homo sapiens 82-85 26478683-10 2015 The study cohort revealed less postoperative pain after TVC comparing to the LC-patients on the day of surgery (NRS, 1.5/10 vs 3.1/10, P = 0.003), in the morning (NRS, 1.9/10 vs 2.8/10, P = 0.047) and in the evening (NRS, 1.1/10 vs 1.8/10, P = 0.025) of postoperative day (POD) one. 3-(Naphthalen-2-yl)benzoic acid 56-59 sphingolipid transporter 1 (putative) Homo sapiens 112-115 25421590-8 2015 After patient education and before application of capsaicin patch, a significant reduction of three levels on the NRS was observed. Capsaicin 50-59 sphingolipid transporter 1 (putative) Homo sapiens 114-117 25512031-5 2015 Patients who received buprenorphine as an adjuvant to the local anaesthetic had significantly longer sensory blockade and lower NRS-rated pain intensity with the difference reaching statistical significance at 12 hours post-surgery. Buprenorphine 22-35 sphingolipid transporter 1 (putative) Homo sapiens 128-131 25842937-7 2014 RESULTS: Application of paracetamol + trimeperidin accompanied with effectively reducing of postoperative pain (less than 5 points on the NRS). Promedol 38-50 sphingolipid transporter 1 (putative) Homo sapiens 138-141 23720078-7 2013 Paracetamol (15 mg.kg-1) was given rectally in the first 6 hours (hrs) and orally over the subsequent 6 hrs, if NRS greater than 3 and CHEOPS greater than 8 were observed. Acetaminophen 0-11 sphingolipid transporter 1 (putative) Homo sapiens 112-115 24435244-10 2014 CONCLUSION: Within a multimodal approach, a single preoperative oral administration of 30 mg of morphine sulphate in patients undergoing LC did not improve pain at rest, but improved NRS on movement during the first 3 hours after awakening. Morphine 96-113 sphingolipid transporter 1 (putative) Homo sapiens 183-186 24646624-9 2014 Within the PA group, the proportion of successful results was significantly higher in the decompression subgroup than in the fusion group according to 6-month posttreatment NRS leg and ODI scores. Protactinium 11-13 sphingolipid transporter 1 (putative) Homo sapiens 173-176 23948565-6 2013 The orientation of 1,4-dibromonaphthlaene (1,4-DBrN) on silver nanoparticles has been inferred from nRs and SERS spectral features. 1,4-dibromonaphthlaene 19-41 sphingolipid transporter 1 (putative) Homo sapiens 100-103 23948565-6 2013 The orientation of 1,4-dibromonaphthlaene (1,4-DBrN) on silver nanoparticles has been inferred from nRs and SERS spectral features. 1,4-dbrn 43-51 sphingolipid transporter 1 (putative) Homo sapiens 100-103 23948565-6 2013 The orientation of 1,4-dibromonaphthlaene (1,4-DBrN) on silver nanoparticles has been inferred from nRs and SERS spectral features. Silver 56-62 sphingolipid transporter 1 (putative) Homo sapiens 100-103 22942098-0 2012 Polymorphisms in sh2b1 and spns1 loci are associated with triglyceride levels in a healthy population in northern Sweden. Triglycerides 58-70 sphingolipid transporter 1 (putative) Homo sapiens 27-32 23064078-6 2012 3 mg of DEX, the mean NRS was improved to 2. Dextromethorphan 8-11 sphingolipid transporter 1 (putative) Homo sapiens 22-25 22008690-5 2011 Intramuscularly 50 mg of meperidin was administered as rescue medication when NRS was above 4. MEPERIDINE HYDROCHLORIDE 25-34 sphingolipid transporter 1 (putative) Homo sapiens 78-81 22870635-7 2012 Our result shows that the wavelet transform de-noising is effective in removing noise from NRS signals of alcohol in vivo. Alcohols 106-113 sphingolipid transporter 1 (putative) Homo sapiens 91-94 22622905-9 2012 RESULTS: At 2 weeks after PA, significant improvement was observed in NRS back, NRS leg, and ODI compared with pretreatment. Protactinium 26-28 sphingolipid transporter 1 (putative) Homo sapiens 70-73 22313580-9 2012 Scores for the methylprednisolone group were significantly improved at 3-month postblock for NRS (2 +- 1.4 vs 5.2 +- 1.7) and LANSS(1) scores (4.14 +- 2.7 vs 14.1 +- 2.8), accompanying symptoms, and analgesic requirements (P < 0.0001). Methylprednisolone 15-33 sphingolipid transporter 1 (putative) Homo sapiens 93-96 21087896-8 2010 Living in an urban area (OR:2.0) and drinking alcohol daily (OR:4.6) were associated only with NRS. Alcohols 46-53 sphingolipid transporter 1 (putative) Homo sapiens 95-98 21598463-4 2011 The switch to the seven-day buprenorphine patch resulted in a clinically significant decrease of the mean pain intensity at rest during the day from 5.3 to 2.9, on physical effort during the day from 7.1 to 3.3, and at night from 4.9 to 1.9 at the end of the study (11-point NRS scale, p<or=0.001). Buprenorphine 28-41 sphingolipid transporter 1 (putative) Homo sapiens 275-278 21591321-6 2010 During treatment with the 7-day buprenorphine patch there was a clinically significant decrease of the mean pain intensity at rest during the day from 5.7 to 2.9, on physical effort during the day from 7.3 to 3.8 and at night from 5.2 to 2.3 (11-point NRS scale, p < or = 0.001). Buprenorphine 32-45 sphingolipid transporter 1 (putative) Homo sapiens 252-255 20848698-9 2010 Patients in the intervention group received significantly more morphine (29.3 vs. 22.6 mg a day, P<0.01), with higher morphine amounts administered to patients with higher NRS scores (P = 0.01). Morphine 121-129 sphingolipid transporter 1 (putative) Homo sapiens 175-178 17853348-10 2007 CONCLUSION: During nasal oxygen administration the severity of dyspnoea, as measured by use of NRS had not decreased, whereas it had significantly decreased after the first opioid administration. Oxygen 25-31 sphingolipid transporter 1 (putative) Homo sapiens 95-98 20627018-9 2010 The NRS number decreased significantly after 6 hours after treating in PVP Group and PVP combined with radiotherapy Group (P < 0.01), which shows basement of pain was rapid. Povidone 71-74 sphingolipid transporter 1 (putative) Homo sapiens 4-7 20627018-9 2010 The NRS number decreased significantly after 6 hours after treating in PVP Group and PVP combined with radiotherapy Group (P < 0.01), which shows basement of pain was rapid. Povidone 85-88 sphingolipid transporter 1 (putative) Homo sapiens 4-7 18349202-8 2008 Dynamic pain was greatly reduced in the dexamethasone group (NRS score: 2.7, 95% CI: 2.2-3.1 vs 6.8, 6.4-7.2; P < 0.0001). Dexamethasone 40-53 sphingolipid transporter 1 (putative) Homo sapiens 61-64 18288069-9 2008 RESULTS: While both groups showed a comparable overall analgesic effect, the baseline values of NRS and NRSm were lower for the sufentanyl group (P<0.001), perhaps as a result of its quicker onset due to higher lipophilicity. Sufentanil 128-138 sphingolipid transporter 1 (putative) Homo sapiens 96-99 11067811-2 2000 Matrix effects hamper the ability of manufacturers to adequately calibrate and validate traceability to the National Reference System for Cholesterol (NRS/CHOL). Cholesterol 138-149 sphingolipid transporter 1 (putative) Homo sapiens 151-154 11067811-3 2000 CDC created the Cholesterol Reference Method Laboratory Network (CRMLN) to improve cholesterol measurement by assisting manufacturers of in vitro diagnostic products with validation of the traceability of their assays to the NRS/CHOL. Cholesterol 16-27 sphingolipid transporter 1 (putative) Homo sapiens 225-228